DS
XENE icon

David Shaw’s Xenon Pharmaceuticals XENE Stock Holding History

David Shaw’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,800
Closed -$1.15M – 5275
2026
Q1 		$1.15M Buy
+19,800
New +$912K ﹤0.01% 3343

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

David Shaw's XENE Position: Q2 2026 in Review

David Shaw increased its Xenon Pharmaceuticals (XENE) stake by 1,082% in Q2 2026, buying an estimated $11.4M and bringing the position to 223,922 shares worth $13.5M. The position accounts for 0.01% of the portfolio, ranked #1581.

David Shaw first reported a position in XENE in Q4 2018 and has held it in 31 quarters since. The position peaked at $14.8M in Q4 2021. 314 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • David Shaw held 223,922 shares of Xenon Pharmaceuticals worth $13.5M as of Q2 2026.
  • David Shaw bought 204,982 Xenon Pharmaceuticals shares in Q2 2026, an estimated $11.4M.
  • Xenon Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1581 holding.
  • David Shaw first reported a position in Xenon Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • David Shaw's Xenon Pharmaceuticals position peaked at $14.8M in Q4 2021.
  • 314 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.